Apixaban, an orally available anticoagulant, inhibits SARS-CoV-2 replication and its major protease in a non-competitive way
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Molecular Cell Biology"
DOI: 10.1093/jmcb/mjac039
Abstract: Dear Editor, The severe coronavirus disease 2019 (COVID-19) is associated with coagulopathy. Anticoagulants, such as low-molecular-weight heparin, warfarin, thrombin inhibitors, and factor Xa (FXa) inhibitors, are thus recommended by the American Society of Hematology and… read more here.
Keywords: adam 2021; protease; orally available; apixaban orally ... See more keywords